Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioXcel Therapeutics, Inc.BTAI · Entity 8380 | Director · CEO and President | June 15, 2026 | June 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioXcel Therapeutics, Inc.
Report date June 15, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 69,817 |
Reported balance
After 2026-06-15 transaction · row 1
1 source rowRow 1 · 2026-06-15 · Exercise / conversion · Acquired 219 · Balance 69,817 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,313 |
Reported balance
After 2026-06-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-15 · Exercise / conversion · Disposed 219 · Balance 1,313 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3: On March 15, 2023, the Reporting Person was granted 3,500 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 125 |
Reported balance
Holding disclosure · report date 2026-06-15 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 125 |
| Common StockSEC Table I · non-derivative | IndirectBy BioXcel LLC | 480,343 |
Reported balance
Holding disclosure · report date 2026-06-15 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 480,343 F2: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Parent"). The Reporting Person is an executive officer and the sole member of the board of directors of Parent and an executive officer and one of two managers on the board of managers of BioXcel LLC and Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Parent"). The Reporting Person is an executive officer and the sole member of the board of directors of Parent and an executive officer and one of two managers on the board of managers of BioXcel LLC and Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.
F3: On March 15, 2023, the Reporting Person was granted 3,500 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2026 Filed Jun 18, 2026 00:00 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 219 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-075298 · tm2618120-1_4seq1.xml · derivative · entry 4 Mehta Vimal · CIK 0001733369 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,313 Underlying: Common Stock · 219 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: On March 15, 2023, the Reporting Person was granted 3,500 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F3 · derivative.expiration_date: On March 15, 2023, the Reporting Person was granted 3,500 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| June 15, 2026 Filed Jun 18, 2026 00:00 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 219 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-075298 · tm2618120-1_4seq1.xml · nonDerivative · entry 1 Mehta Vimal · CIK 0001733369 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,817 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| May 20, 2026 Filed May 22, 2026 23:00 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | SaleCommon Stock | 19,419 | $1.09 | $21,108.45 |
DisclosureSEC source: 0001104659-26-065836 · tm2615413-1_4seq1.xml · nonDerivative · entry 2 Mehta Vimal · CIK 0001733369 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,598 F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 3, 2026 solely to cover taxes due in connection with the vesting of restricted stock units. F3 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $1.07 to $1.105. The Reporting Person undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 04, 2026 Filed May 22, 2026 23:00 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 49,758 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-065836 · tm2615413-1_4seq1.xml · derivative · entry 5 Mehta Vimal · CIK 0001733369 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 149,274 Underlying: Common Stock · 49,758 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: On January 1, 2026, the Reporting Person was granted 199,032 RSUs, vesting as to 25% of the underlying shares on the six-month anniversary of the original promise date of November 4, 2025 (the "Vesting Commencement Date"), with the remaining 75% vesting in three equal installments of 25% on the last day of each subsequent six-month period thereafter, such that the RSUs are fully vested on the two-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F5 · derivative.expiration_date: On January 1, 2026, the Reporting Person was granted 199,032 RSUs, vesting as to 25% of the underlying shares on the six-month anniversary of the original promise date of November 4, 2025 (the "Vesting Commencement Date"), with the remaining 75% vesting in three equal installments of 25% on the last day of each subsequent six-month period thereafter, such that the RSUs are fully vested on the two-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| May 04, 2026 Filed May 22, 2026 23:00 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 49,758 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-065836 · tm2615413-1_4seq1.xml · nonDerivative · entry 1 Mehta Vimal · CIK 0001733369 · Director · CEO and President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,017 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| May 01, 2026 Filed May 7, 2026 23:01 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 18,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-057367 · tm2613630-4_4seq1.xml · derivative · entry 4 Mehta Vimal · CIK 0001733369 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: On August 1, 2025 (the "Grant Date"), the Reporting Person was granted 18,000 RSUs, vesting as to 100% on or within thirty (30) days of 9 months from the Grant Date, subject to the Reporting Person's continued employment with the Issuer or a subsidiary of the Issuer on such date. F3 · derivative.expiration_date: On August 1, 2025 (the "Grant Date"), the Reporting Person was granted 18,000 RSUs, vesting as to 100% on or within thirty (30) days of 9 months from the Grant Date, subject to the Reporting Person's continued employment with the Issuer or a subsidiary of the Issuer on such date. Read SEC document |
| May 01, 2026 Filed May 7, 2026 23:01 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 18,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-057367 · tm2613630-4_4seq1.xml · nonDerivative · entry 1 Mehta Vimal · CIK 0001733369 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,259 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 00:05 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 219 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-028722 · tm268882-4_4seq1.xml · derivative · entry 6 Mehta Vimal · CIK 0001733369 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,532 Underlying: Common Stock · 219 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: On March 15, 2023, the Reporting Person was granted 3,500 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F4 · derivative.expiration_date: On March 15, 2023, the Reporting Person was granted 3,500 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 00:05 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 219 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-028722 · tm268882-4_4seq1.xml · nonDerivative · entry 2 Mehta Vimal · CIK 0001733369 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,259 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| March 14, 2026 Filed Mar 17, 2026 00:05 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 164 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-028722 · tm268882-4_4seq1.xml · derivative · entry 5 Mehta Vimal · CIK 0001733369 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 488 Underlying: Common Stock · 164 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: On March 14, 2022, the Reporting Person was granted 2,609 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F3 · derivative.expiration_date: On March 14, 2022, the Reporting Person was granted 2,609 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| March 14, 2026 Filed Mar 17, 2026 00:05 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 164 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-028722 · tm268882-4_4seq1.xml · nonDerivative · entry 1 Mehta Vimal · CIK 0001733369 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,040 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| January 01, 2026 Filed Jan 6, 2026 01:00 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantRestricted Stock Units · Derivative | 199,032 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-000835 · tm261931-2_4seq1.xml · derivative · entry 1 Mehta Vimal · CIK 0001733369 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,783 Underlying: Common Stock · 199,032 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: On January 1, 2026, the Reporting Person was granted 199,032 RSUs, vesting as to 25% of the underlying shares on the six-month anniversary of the original promise date of November 4, 2025 (the "Vesting Commencement Date"), with the remaining 75% vesting in three equal installments of 25% on the last day of each subsequent six-month period thereafter, such that the RSUs are fully vested on the two-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F2 · derivative.expiration_date: On January 1, 2026, the Reporting Person was granted 199,032 RSUs, vesting as to 25% of the underlying shares on the six-month anniversary of the original promise date of November 4, 2025 (the "Vesting Commencement Date"), with the remaining 75% vesting in three equal installments of 25% on the last day of each subsequent six-month period thereafter, such that the RSUs are fully vested on the two-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| December 15, 2025 Filed Dec 16, 2025 01:02 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 219 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-121304 · tm2533410-4_4seq1.xml · derivative · entry 6 Mehta Vimal · CIK 0001733369 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,751 Underlying: Common Stock · 219 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: On March 15, 2023, the Reporting Person was granted 3,500 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F4 · derivative.expiration_date: On March 15, 2023, the Reporting Person was granted 3,500 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| December 15, 2025 Filed Dec 16, 2025 01:02 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 219 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-121304 · tm2533410-4_4seq1.xml · nonDerivative · entry 2 Mehta Vimal · CIK 0001733369 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,876 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| December 14, 2025 Filed Dec 16, 2025 01:02 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 164 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-121304 · tm2533410-4_4seq1.xml · derivative · entry 5 Mehta Vimal · CIK 0001733369 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 652 Underlying: Common Stock · 164 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: On March 14, 2022, the Reporting Person was granted 2,609 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F3 · derivative.expiration_date: On March 14, 2022, the Reporting Person was granted 2,609 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| December 14, 2025 Filed Dec 16, 2025 01:02 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 164 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-121304 · tm2533410-4_4seq1.xml · nonDerivative · entry 1 Mehta Vimal · CIK 0001733369 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,657 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| September 15, 2025 Filed Sep 16, 2025 23:05 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 219 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-090518 · tm2526247-4_4seq1.xml · derivative · entry 6 Mehta Vimal · CIK 0001733369 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,970 Underlying: Common Stock · 219 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: On March 15, 2023, the Reporting Person was granted 3,500 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F4 · derivative.expiration_date: On March 15, 2023, the Reporting Person was granted 3,500 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| September 15, 2025 Filed Sep 16, 2025 23:05 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 219 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-090518 · tm2526247-4_4seq1.xml · nonDerivative · entry 2 Mehta Vimal · CIK 0001733369 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,493 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| September 14, 2025 Filed Sep 16, 2025 23:05 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 163 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-090518 · tm2526247-4_4seq1.xml · derivative · entry 5 Mehta Vimal · CIK 0001733369 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 816 Underlying: Common Stock · 163 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: On March 14, 2022, the Reporting Person was granted 2,609 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F3 · derivative.expiration_date: On March 14, 2022, the Reporting Person was granted 2,609 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| September 14, 2025 Filed Sep 16, 2025 23:05 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 163 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-090518 · tm2526247-4_4seq1.xml · nonDerivative · entry 1 Mehta Vimal · CIK 0001733369 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,274 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| August 01, 2025 Filed Aug 6, 2025 00:00 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantRestricted Stock Units · Derivative | 18,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-074369 · tm2522669-1_4seq1.xml · derivative · entry 1 Mehta Vimal · CIK 0001733369 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: On August 1, 2025 (the "Grant Date"), the Reporting Person was granted 18,000 RSUs, vesting as to 100% on or within thirty (30) days of 9 months from the Grant Date, subject to the Reporting Person's continued employment with the Issuer or a subsidiary of the Issuer on such date. F2 · derivative.expiration_date: On August 1, 2025 (the "Grant Date"), the Reporting Person was granted 18,000 RSUs, vesting as to 100% on or within thirty (30) days of 9 months from the Grant Date, subject to the Reporting Person's continued employment with the Issuer or a subsidiary of the Issuer on such date. Read SEC document |
| July 22, 2025 Filed Jul 23, 2025 00:29 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantCommon Stock | 15,625 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-069703 · tm2521458-4_4seq1.xml · nonDerivative · entry 1 Mehta Vimal · CIK 0001733369 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,111 F1 · price: The Issuer previously granted the Reporting Person an award of restricted stock units that would vest based on the Issuer's satisfaction of certain performance objectives and subject to the Reporting Person's continued service with the Issuer through July 22, 2025 (the "PSUs"). On July 22, 2025, the Compensation Committee of the Issuer's Board of Directors determined that performance conditions with respect to 15,625 PSUs had been satisfied and 15,625 shares of common stock became issuable to the Reporting Person on July 22, 2025. Read SEC document |
| June 15, 2025 Filed Jun 16, 2025 23:01 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 219 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-059980 · tm2518140-2_4seq1.xml · derivative · entry 6 Mehta Vimal · CIK 0001733369 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,189 Underlying: Common Stock · 219 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: On March 15, 2023, the Reporting Person was granted 3,500 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F4 · derivative.expiration_date: On March 15, 2023, the Reporting Person was granted 3,500 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| June 15, 2025 Filed Jun 16, 2025 23:01 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 219 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-059980 · tm2518140-2_4seq1.xml · nonDerivative · entry 2 Mehta Vimal · CIK 0001733369 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,486 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| June 14, 2025 Filed Jun 16, 2025 23:01 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 163 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-059980 · tm2518140-2_4seq1.xml · derivative · entry 5 Mehta Vimal · CIK 0001733369 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 979 Underlying: Common Stock · 163 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: On March 14, 2022, the Reporting Person was granted 2,609 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F3 · derivative.expiration_date: On March 14, 2022, the Reporting Person was granted 2,609 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| June 14, 2025 Filed Jun 16, 2025 23:01 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 163 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-059980 · tm2518140-2_4seq1.xml · nonDerivative · entry 1 Mehta Vimal · CIK 0001733369 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,267 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| March 15, 2025 Filed Mar 17, 2025 22:35 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 217 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-024531 · tm259558-1_4seq1.xml · derivative · entry 6 Mehta Vimal · CIK 0001733369 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,408 Underlying: Common Stock · 217 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: On March 15, 2023, the Reporting Person was granted 3,500 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F4 · derivative.expiration_date: On March 15, 2023, the Reporting Person was granted 3,500 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| March 15, 2025 Filed Mar 17, 2025 22:35 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 217 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-024531 · tm259558-1_4seq1.xml · nonDerivative · entry 2 Mehta Vimal · CIK 0001733369 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,104 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| March 14, 2025 Filed Mar 17, 2025 22:35 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 162 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-024531 · tm259558-1_4seq1.xml · derivative · entry 5 Mehta Vimal · CIK 0001733369 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,142 Underlying: Common Stock · 162 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: On March 14, 2022, the Reporting Person was granted 2,609 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F3 · derivative.expiration_date: On March 14, 2022, the Reporting Person was granted 2,609 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| March 14, 2025 Filed Mar 17, 2025 22:35 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 162 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-024531 · tm259558-1_4seq1.xml · nonDerivative · entry 1 Mehta Vimal · CIK 0001733369 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,887 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| January 07, 2025 Filed Jan 11, 2025 01:03 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Option (right to buy) · Derivative | 660,000 | $0.00 Strike: $0.47 | $0.00 |
DisclosureSEC source: 0001104659-25-002693 · tm252892-4_4seq1.xml · derivative · entry 1 Mehta Vimal · CIK 0001733369 · Director · CEO and President · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 660,000 Underlying: Common Stock · 660,000 shares Expires 2035-01-07 F1 · derivative.exercise_date: On January 7, 2025, the Reporting Person was granted an option to purchase 660,000 shares of common stock, which vests in twelve equal monthly installments over a twelve-month period following the grant date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| December 16, 2024 Filed Dec 17, 2024 23:08 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | SaleCommon Stock | 2,134 | $0.36 | $773.36 |
DisclosureSEC source: 0001104659-24-129462 · tm2431371-4_4seq1.xml · nonDerivative · entry 4 Mehta Vimal · CIK 0001733369 · Director · CEO and President · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,605 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023. F3 · price: The price reported is a weighted average price. The Reporting Person undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 16, 2024 Filed Dec 17, 2024 23:08 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | SaleCommon Stock | 983 | $0.36 | $357.91 |
DisclosureSEC source: 0001104659-24-129462 · tm2431371-4_4seq1.xml · nonDerivative · entry 3 Mehta Vimal · CIK 0001733369 · Director · CEO and President · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,920 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023. F3 · price: The price reported is a weighted average price. The Reporting Person undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 15, 2024 Filed Dec 17, 2024 23:08 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 3,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-129462 · tm2431371-4_4seq1.xml · derivative · entry 8 Mehta Vimal · CIK 0001733369 · Director · CEO and President · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,500 Underlying: Common Stock · 3,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F6 · derivative.exercise_date: On March 15, 2023, the Reporting Person was granted 56,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F6 · derivative.expiration_date: On March 15, 2023, the Reporting Person was granted 56,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| December 15, 2024 Filed Dec 17, 2024 23:08 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 3,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-129462 · tm2431371-4_4seq1.xml · nonDerivative · entry 2 Mehta Vimal · CIK 0001733369 · Director · CEO and President · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,903 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| December 14, 2024 Filed Dec 17, 2024 23:08 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 2,610 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-129462 · tm2431371-4_4seq1.xml · derivative · entry 7 Mehta Vimal · CIK 0001733369 · Director · CEO and President · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,049 Underlying: Common Stock · 2,610 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: On March 14, 2022, the Reporting Person was granted 41,750 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F5 · derivative.expiration_date: On March 14, 2022, the Reporting Person was granted 41,750 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| December 14, 2024 Filed Dec 17, 2024 23:08 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 2,610 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-129462 · tm2431371-4_4seq1.xml · nonDerivative · entry 1 Mehta Vimal · CIK 0001733369 · Director · CEO and President · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,403 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 23:21 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | SaleCommon Stock | 1,150 | $0.69 | $794.08 |
DisclosureSEC source: 0001104659-24-100751 · tm2424255-6_4seq1.xml · nonDerivative · entry 4 Mehta Vimal · CIK 0001733369 · Director · CEO and President · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,666 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 23:21 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | SaleCommon Stock | 832 | $0.69 | $572.83 |
DisclosureSEC source: 0001104659-24-100751 · tm2424255-6_4seq1.xml · nonDerivative · entry 3 Mehta Vimal · CIK 0001733369 · Director · CEO and President · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,816 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023. Read SEC document |
| September 15, 2024 Filed Sep 17, 2024 23:21 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 3,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-100751 · tm2424255-6_4seq1.xml · derivative · entry 8 Mehta Vimal · CIK 0001733369 · Director · CEO and President · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 3,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: On March 15, 2023, the Reporting Person was granted 56,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F5 · derivative.expiration_date: On March 15, 2023, the Reporting Person was granted 56,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| September 15, 2024 Filed Sep 17, 2024 23:21 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 3,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-100751 · tm2424255-6_4seq1.xml · nonDerivative · entry 2 Mehta Vimal · CIK 0001733369 · Director · CEO and President · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,648 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| September 14, 2024 Filed Sep 17, 2024 23:21 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 2,609 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-100751 · tm2424255-6_4seq1.xml · derivative · entry 7 Mehta Vimal · CIK 0001733369 · Director · CEO and President · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,657 Underlying: Common Stock · 2,609 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: On March 14, 2022, the Reporting Person was granted 41,750 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F4 · derivative.expiration_date: On March 14, 2022, the Reporting Person was granted 41,750 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| September 14, 2024 Filed Sep 17, 2024 23:21 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 2,609 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-100751 · tm2424255-6_4seq1.xml · nonDerivative · entry 1 Mehta Vimal · CIK 0001733369 · Director · CEO and President · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,148 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| July 22, 2024 Filed Apr 1, 2025 22:08 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Option (right to buy) · Derivative | 6,250 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001104659-25-030686 · tm2511097-6_4seq1.xml · derivative · entry 1 Mehta Vimal · CIK 0001733369 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,250 Underlying: Common Stock · 6,250 shares Expires 2034-07-22 F1 · shares: The share amount has been adjusted to reflect the reverse stock split effective on February 7, 2025 whereby every sixteen shares issued and outstanding prior to the split were combined and converted into one share of common stock. F2 · derivative.exercise_date: The Reporting Person was granted an option to purchase 6,250 shares of common stock, which vests as to 50% on each of the first and second anniversaries of the grant date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| June 17, 2024 Filed Jun 19, 2024 01:24 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | SaleCommon Stock | 2,134 | $1.28 | $2,738.99 |
DisclosureSEC source: 0001104659-24-072999 · tm2417544-1_4seq1.xml · nonDerivative · entry 3 Mehta Vimal · CIK 0001733369 · Director · CEO and President · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,539 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023. F3 · price: The price reported in a weighted average price. The securities were sold in multiple transactions at a per share prices ranging from $1.275 to $1.295. The Reporting Person undertakes to provide upon request the Securities and Exchange Commission staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sole at each separate price within the range set forth in this footnote. Read SEC document |
| June 15, 2024 Filed Jun 19, 2024 01:24 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 3,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-072999 · tm2417544-1_4seq1.xml · derivative · entry 7 Mehta Vimal · CIK 0001733369 · Director · CEO and President · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,500 Underlying: Common Stock · 3,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F6 · derivative.exercise_date: On March 15, 2023, the Reporting Person was granted 56,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F6 · derivative.expiration_date: On March 15, 2023, the Reporting Person was granted 56,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| June 15, 2024 Filed Jun 19, 2024 01:24 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 3,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-072999 · tm2417544-1_4seq1.xml · nonDerivative · entry 2 Mehta Vimal · CIK 0001733369 · Director · CEO and President · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,673 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| June 14, 2024 Filed Jun 19, 2024 01:24 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 2,609 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-072999 · tm2417544-1_4seq1.xml · derivative · entry 6 Mehta Vimal · CIK 0001733369 · Director · CEO and President · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,266 Underlying: Common Stock · 2,609 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: On March 14, 2022, the Reporting Person was granted 41,750 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F5 · derivative.expiration_date: On March 14, 2022, the Reporting Person was granted 41,750 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| June 14, 2024 Filed Jun 19, 2024 01:24 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 2,609 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-072999 · tm2417544-1_4seq1.xml · nonDerivative · entry 1 Mehta Vimal · CIK 0001733369 · Director · CEO and President · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,173 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 20:35 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | SaleCommon Stock | 126,014 | $1.58 | $199,618.78 |
DisclosureSEC source: 0001104659-24-069195 · tm2416676-1_4seq1.xml · nonDerivative · entry 5 Mehta Vimal · CIK 0001733369 · Director · CEO and President · 10% owner BioXcel Holdings, Inc. · CIK 0001811154 · 10% owner BioXcel LLC · CIK 0001651990 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By BioXcel LLC Disclosed balance after: 7,685,501 F4 · kind: Represents sales of an amount of shares of Common Stock sufficient to cover certain tax liabilities incurred in connection with the transfers of Common Stock reported herein. F6 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at a per share prices ranging from $1.55 to $1.635. The Reporting Persons undertake to provide upon request of the Securities and Exchange Commission staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Parent"). Vimal Mehta, Ph.D. is an executive officer and the sole member of the board of directors of Parent and an executive officer and one of two managers on the board of managers of BioXcel LLC. By virtue of these relationships, Parent and Dr. Mehta may be deemed to be the beneficial owners of the securities held of record by BioXcel LLC. Each disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.